University of Campinas
Campinas, São Paulo, 13083-888, Brazil
NCT Number: NCT01388582
The investigators propose a randomized clinical trial comparing the effect of 30 mcg ethinyl estradiol and LNG 150 combination oral contraceptive pills versus placebo, or LNG-IUS or Etonogestrel-releasing contraceptive implant (Implanon)on breast-milk intake and infant growth in exclusively breastfeeding mother-infant pairs. Mother-infant pairs will be randomly assigned either 30 microgram ethinyl estradiol combination oral contraceptive pills or identical placebo to start on post-partum day number 42 or Implanon implants or a LNG-IUS. All women will be offered nonhormonal contraceptives prior to randomization. The pairs will then be followed for four weeks. During this follow-up period, breast-milk intake will be quantified by administering deuterium oxide to exclusively breast-feeding mothers and measuring the enrichment of deuterium oxide in the saliva of their infants, otherwise known as the dose-to-mother method of Coward.17 Additionally, maternal and infant anthropometric measurements will be collected -- both as a value necessary to implement the breast-milk quantification method, as well as an outcome for analysis, and a daily diary will be kept by the women participating in the study that records infant feeds and diaper changes.
Looking for future studies?
Notify Me18 year–40 year
Female
Interventional
Phase 4
Campinas, São Paulo, 13083-888, Brazil
Women where allocated to an oral combined contraceptive pill, or placebo or a LNG-IUS or a etonogestrel-releasing subdermal contraceptive implant at day 42 after delivery. After the provision of the contraceptive method a 0.5 mg/kg of deuterium 99.99% according to the weight of the mother will be administer to all women. One sample of saliva from the mother and the child will be collected every day until 21 days after enrollment. Additionally, weight, height and size of the leg of each child will be measured at baseline, at the day 11 and at the day 21 after enrollment. Also, a diary with information of change of diapers and number of breastfeeding will be kept by each mother.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10 women will receive the LNG-IUS during breastfeeding
Other names: Mirena, Bayer, Brazil
60 mcg/day contraceptive implant
Other names: Implanon, MSD, Brazil
10 women will receive oral contraceptive during breastfeeding
Other names: Microvlar (Bayer, Brazil)
Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
Other names: Optima IUD (Injeflex, Brazil)
10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
Other names: Implanon, MSD, Os, The Netherland, Mirena, Bayer Oy, Tuku, Finland, TCu380A copper intrauterine device; Optima, Injeflex, Brazil, Microvlar oral contraceptive, Bayer, São Paulo, Brazil
Time frame: women and children will be evaluated at time frame from day 42 through day 64 post-partum
The study have the purpose to evaluate the infant weight, height and size of the tibial in infant who breastfeeding on demand exclusively and their mother were either users of a combined oral contraceptive, placebo, etonogestrel-releasing subdermal contraceptive implant or levonorgestrel-releasing intrauterine system. Additionally, pregnancy effectiveness and any adversse event will record in all groups of women.
University of Campinas, Brazil
Other
The Effect of 30mcg and Levonorgestrel 150 Combined Oral Contraceptive, Etonogestrel-releasing Subdermal Implant and Levonorgestrel-releasing Intrauterine System on Breast-Milk Production and Infant Growth in Fully Breast-Feeding Women
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04704076
Behavior, Body Weight
Bissau, Guinea-Bissau
View Trial DetailsNCT05648045
Behavior, Body Weight
Kolkata, West Bengal, India
View Trial DetailsNCT06729359
Adnexal Diseases, BMI
Baghdad, Alrusafa, Iraq
View Trial DetailsNCT05517395
Body Weight, Body Weight Changes
Taipei County, Taipei, Taiwan
View Trial Details